IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC raised its stake in IDEAYA Biosciences by 20.8% in the first quarter, owning 138,855 shares valued at $2,274,000 as per its latest SEC filing.
• Equities analysts have issued mixed ratings for IDEAYA, with Royal Bank of Canada adjusting its rating from "outperform" to "moderate buy" and lowering the price target from $57.00 to $30.00.
• IDEAYA Biosciences reported a missing EPS estimate of ($0.88) for the last quarter, although its revenue of $6.00 million exceeded expectations of $3.48 million.

Jump Financial LLC increased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 20.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,855 shares of the company's stock after purchasing an additional 23,953 shares during the quarter. Jump Financial LLC owned 0.16% of IDEAYA Biosciences worth $2,274,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in IDYA. CWM LLC boosted its stake in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the period. PNC Financial Services Group Inc. boosted its stake in IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after acquiring an additional 1,546 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in IDEAYA Biosciences during the 4th quarter valued at $47,000. Signaturefd LLC boosted its stake in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after acquiring an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in IDEAYA Biosciences by 46.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after acquiring an additional 2,112 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded down $0.38 during trading hours on Friday, reaching $24.55. The stock had a trading volume of 632,810 shares, compared to its average volume of 877,057. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $40.25. The firm has a 50-day simple moving average of $23.26 and a 200-day simple moving average of $20.47. The firm has a market capitalization of $2.15 billion, a PE ratio of -6.48 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. During the same quarter in the previous year, the business posted ($0.68) earnings per share. The firm's revenue for the quarter was up NaN% on a year-over-year basis. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analyst Ratings Changes

IDYA has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a research note on Thursday, July 10th. TD Cowen began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and reduced their price target for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $47.10.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.